On estimating treatment effects under non-compliance in randomized clinical trials: Are intent-to-treat or instrumental variables analyses perfect solutions?

Statistics in Medicine

Volumn 26, Issue 5, 2007, Pages 954-964

  Bang, Heejung ^a   Davis, Clarence E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b IL   (United States)

Author keywords

As treated; Clinical trial; Instrumental variables; Intent to treat; Non compliance; Per protocol; Treatment effect

Indexed keywords

ARTICLE; BIOSTATISTICS; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPARATIVE STUDY; CONFIDENCE INTERVAL; INFERENTIAL STATISTICS; PATIENT COMPLIANCE; PREDICTOR VARIABLE; SIMULATION; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

HUMANS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES;

EID: 33847133828     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2663     Document Type: Article

References (18)

1. Little RJ, Rubin, DB. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annual Review of Public Health 2000; 21:121-145.
2. Wald A. The fitting of straight lines if both variables are subject to error. The Annals of Mathematica Statistics 1940; 11:284-300.
3. Durbin J. Errors in variables. Review of the International Statistical Institute 1954; 22:23-32.
4. Sommer A, Zeger, SL. On estimating efficacy from clinical trials. Statistics in Medicine 1991; 10:45-52.
5. Hodges J, Lehmann E. Estimates of location based on rank tests. Annals of Mathematical Statistics 1963; 34:598-611.
6. Rosenbaum PR. Comment on Angrist, Imbens, and Rubins's article. Journal of the American Statistical Association 1996; 91:465-468.
7. Greevy RA, Silber JH, Cnaan A, Rosenbaum PR. Randomization inference with imperfect compliance in the ACE-Inhibitor after Anthracycline randomized trial. Journal of the American Statistical Association 2004; 99:7-15.
8. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables (with discussion). Journal of the American Statistical Association 1996; 91:444-455.
9. O'Malley AJ, Normand ST. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials. Biometrics 2005; 61:325-334.
10. Rosenbaum P, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. Journal of the Royal Statistical Society B 1983; 45:212-218.
11. Fieller EC. Some problems in interval estimation. Journal of the Royal Statistical Society B 1954; 16:175-185.
12. Hirano K, Imbens GW, Rubin DB, Zhou X-H. Assessing the effect of an influenza vaccine in an encouragement design. Biostatistics 2000; 1:69-88.
13. Zelen M. A new design for randomized clinical trials. New England Journal of Medicine 1979; 300:1242-1245.
14. Robins JM, Greenland S. Comment on Angrist, Imbens, and Rubins's article. Journal of the American Statistical Association 1996; 91:456-458.
15. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 2002; 58:21-29.
16. Willan AR, O'Brian BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996; 5:297-305. Errata in 1999; 8:559.
17. Zhao H, Tian L. On estimating medical cost and incremental cost-effectiveness ratios with censored data. Biometrics 2001; 57:1002-1008.
18. Imbens GW, Rosenbaum PR. Robust, accurate confidence intervals with a weak instrument: quarter of birth and education. Journal of the Royal Statistical Society A 2005; 168:109-126.